1
|
Morin G, Degrugillier-Chopinet C, Vincent M, Fraissenon A, Aubert H, Chapelle C, Hoguin C, Dubos F, Catteau B, Petit F, Mezel A, Domanski O, Herbreteau G, Alesandrini M, Boddaert N, Boutry N, Broissand C, Han TK, Branle F, Sarnacki S, Blanc T, Guibaud L, Canaud G. Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib. J Exp Med 2022; 219:212982. [PMID: 35080595 PMCID: PMC8932545 DOI: 10.1084/jem.20212148] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Revised: 11/25/2021] [Accepted: 01/03/2022] [Indexed: 12/04/2022] Open
Abstract
PIK3CA-related overgrowth spectrum (PROS) includes rare genetic conditions due to gain-of-function mutations in the PIK3CA gene. There is no approved medical therapy for patients with PROS, and alpelisib, an approved PIK3CA inhibitor in oncology, showed promising results in preclinical models and in patients. Here, we report for the first time the outcome of two infants with PROS having life-threatening conditions treated with alpelisib (25 mg) and monitored with pharmacokinetics. Patient 1 was an 8-mo-old girl with voluminous vascular malformation. Patient 2 was a 9-mo-old boy presenting with asymmetrical body overgrowth and right hemimegalencephaly with West syndrome. After 12 mo of follow-up, alpelisib treatment was associated with improvement in signs and symptoms, morphological lesions and vascular anomalies in the two patients. No adverse events were reported during the study. In this case series, pharmacological inhibition of PIK3CA with low-dose alpelisib was feasible and associated with clinical improvements, including a smaller size of associated complex tissue malformations and good tolerability.
Collapse
Affiliation(s)
- Gabriel Morin
- Université de Paris, Paris, France.,Institut national de la santé et de la recherche médicale U1151, Institut Necker-Enfants Malades, Paris, France.,Unité d'Hypercroissance Dysharmonieuse et Anomalies Vasculaires, Hôpital Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Caroline Degrugillier-Chopinet
- Service de Physiologie & Explorations Fonctionnelles Cardiovasculaires, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Marie Vincent
- Service de Génétique Médicale, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Antoine Fraissenon
- Institut national de la santé et de la recherche médicale U1151, Institut Necker-Enfants Malades, Paris, France.,Service d'Imagerie Pédiatrique, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France.,Service de Radiologie Mère-Enfant, Hôpital Nord, Saint Etienne, France.,CREATIS Unité mixte de recherche 5220, Villeurbanne, France
| | - Hélène Aubert
- Service de Dermatologie, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Célia Chapelle
- Institut national de la santé et de la recherche médicale U1151, Institut Necker-Enfants Malades, Paris, France.,Unité d'Hypercroissance Dysharmonieuse et Anomalies Vasculaires, Hôpital Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Clément Hoguin
- Université de Paris, Paris, France.,Institut national de la santé et de la recherche médicale U1151, Institut Necker-Enfants Malades, Paris, France
| | - François Dubos
- Urgences Pédiatriques et Maladies Infectieuses, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Benoit Catteau
- Clinique de Dermatologie, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Florence Petit
- Clinique de Génétique, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Aurélie Mezel
- Service d'Orthopédie Pédiatrique, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Olivia Domanski
- Service de Cardiologie Pédiatrique et Congénitale, Centre Hospitalier Universitaire de Lille, Lille, France
| | - Guillaume Herbreteau
- Laboratoire de Biochimie, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Marie Alesandrini
- Service de Pédiatrie, Centre Hospitalier Universitaire de Nantes, Nantes, France
| | - Nathalie Boddaert
- Université de Paris, Paris, France.,Service d'Imagerie Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France
| | - Nathalie Boutry
- Service de Radiologie et Imagerie de l'Enfant, Centre Hospitalier Universitaire Jeanne de Flandre, Lille, France
| | - Christine Broissand
- Pharmacie, Hôpital Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Paris, France
| | | | | | - Sabine Sarnacki
- Université de Paris, Paris, France.,Service de Chirurgie Viscérale Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France
| | - Thomas Blanc
- Université de Paris, Paris, France.,Service de Chirurgie Viscérale Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France
| | - Laurent Guibaud
- Service d'Imagerie Pédiatrique, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France
| | - Guillaume Canaud
- Université de Paris, Paris, France.,Institut national de la santé et de la recherche médicale U1151, Institut Necker-Enfants Malades, Paris, France.,Unité d'Hypercroissance Dysharmonieuse et Anomalies Vasculaires, Hôpital Necker-Enfants Malades, Assistance Publique - Hôpitaux de Paris, Paris, France
| |
Collapse
|
2
|
Cai H, Zhang Y, Han TK, Everett RS, Thakker DR. Cation-selective transporters are critical to the AMPK-mediated antiproliferative effects of metformin in human breast cancer cells. Int J Cancer 2016; 138:2281-92. [DOI: 10.1002/ijc.29965] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2015] [Accepted: 12/03/2015] [Indexed: 01/01/2023]
Affiliation(s)
- Hao Cai
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy; the University of North Carolina at Chapel Hill; Chapel Hill NC
| | - Yunhui Zhang
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy; the University of North Carolina at Chapel Hill; Chapel Hill NC
- Research Center for Drug Metabolism, Jilin University; Changchun People's Republic of China
| | - Tianxiang Kevin Han
- Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy; the University of North Carolina at Chapel Hill; Chapel Hill NC
| | - Ruth S. Everett
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy; the University of North Carolina at Chapel Hill; Chapel Hill NC
| | - Dhiren R. Thakker
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy; the University of North Carolina at Chapel Hill; Chapel Hill NC
| |
Collapse
|
3
|
Lee SH, Hong HR, Han TK, Kang HS. Aerobic training increases the expression of adiponectin receptor genes in the peripheral blood mononuclear cells of young men. Biol Sport 2015; 32:181-6. [PMID: 26424919 PMCID: PMC4577554 DOI: 10.5604/20831862.1150298] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Revised: 12/01/2014] [Accepted: 02/12/2015] [Indexed: 11/13/2022] Open
Abstract
Little is known about the effect of exercise training on the expression of adiponectin receptor genes in peripheral blood mononuclear cells (PBMCs). In this study, we investigated the effects of aerobic training on the expression of AdipoR1 and AidpoR2 mRNAs in PBMCs, whole body insulin sensitivity, and circulating adiponectins in men. Thirty young men were randomly assigned to either a control (n=15) or an exercise (n=15) group. Subjects assigned to the exercise group underwent a 12-week jogging and/or running programme on a motor-driven treadmill at an intensity of 60%-75% of the age-based maximum heart rate with duration of 40 minutes per session and a frequency of 5 days per week. Two-way mixed ANOVA with repeated measures was used to test any significant time-by-group interaction effects for the measured variables at p=0.05. We found significant time-by-group interaction effects for waist circumference (p=0.001), VO2max (p<0.001), fasting insulin (p=0.016), homeostasis model assessment for insulin resistance (HOMA-IR) (p=0.010), area under the curve (AUC) for insulin response during the 75-g oral glucose tolerance test (p=0.002), high-molecular weight (HMW) adiponectin (p=0.016), and the PBMC mRNA levels of AdipoR1 (p<0.001) and AdipoR2 (p=0.001). The exercise group had significantly increased mRNA levels of AdipoR1 and AdipoR2 in PBMCs, along with increased whole body insulin sensitivity and HMW adiponectin, decreased waist circumference, and increased VO2max compared with the control group. In summary, the current findings suggest that exercise training modulates the expression of AdipoR1 and AdipoR2 mRNAs in PBMCs, implying that manipulation of the expression of these genes could be a potential surrogate for lifestyle intervention-mediated improvements of whole body insulin sensitivity and glucose homeostasis.
Collapse
Affiliation(s)
- S H Lee
- Pohang University of Science and Technology, Pohang, Republic of Korea
| | - H R Hong
- College of Sport Science, Sungkyunkwan University, Suwon, Republic of Korea
| | - T K Han
- College of Sport Science, Sungkyunkwan University, Suwon, Republic of Korea
| | - H S Kang
- College of Sport Science, Sungkyunkwan University, Suwon, Republic of Korea
| |
Collapse
|
4
|
Han TK, Proctor WR, Costales CL, Cai H, Everett RS, Thakker DR. Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers. J Pharmacol Exp Ther 2015; 352:519-28. [PMID: 25563903 DOI: 10.1124/jpet.114.220350] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Metformin is the frontline therapy for type II diabetes mellitus. The oral bioavailability of metformin is unexpectedly high, between 40 and 60%, given its hydrophilicity and positive charge at all physiologic pH values. Previous studies in Caco-2 cell monolayers, a cellular model of the human intestinal epithelium, showed that during absorptive transport metformin is taken up into the cells via transporters in the apical (AP) membrane; however, predominant transport to the basolateral (BL) side occurs via the paracellular route because intracellular metformin cannot egress across the BL membrane. Furthermore, these studies have suggested that the AP transporters can contribute to intestinal accumulation and absorption of metformin. Transporter-specific inhibitors as well as a novel approach involving a cocktail of transporter inhibitors with overlapping selectivity were used to identify the AP transporters that mediate metformin uptake in Caco-2 cell monolayers; furthermore, the relative contributions of these transporters in metformin AP uptake were also determined. The organic cation transporter 1, plasma membrane monoamine transporter (PMAT), serotonin reuptake transporter, and choline high-affinity transporter contributed to approximately 25%, 20%, 20%, and 15%, respectively, of the AP uptake of metformin. PMAT-knockdown Caco-2 cells were constructed to confirm the contribution of PMAT in metformin AP uptake because a PMAT-selective inhibitor is not available. The identification of four intestinal transporters that contribute to AP uptake and potentially intestinal absorption of metformin is a significant novel finding that can influence our understanding of metformin pharmacology and intestinal drug-drug interactions involving this highly prescribed drug.
Collapse
Affiliation(s)
- Tianxiang Kevin Han
- Division of Molecular Pharmaceutics (T.H., W.R.P., C.L.C.) and Division of Pharmacotherapy and Experimental Therapeutics (H.C., R.S.E., D.R.T.), UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - William R Proctor
- Division of Molecular Pharmaceutics (T.H., W.R.P., C.L.C.) and Division of Pharmacotherapy and Experimental Therapeutics (H.C., R.S.E., D.R.T.), UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Chester L Costales
- Division of Molecular Pharmaceutics (T.H., W.R.P., C.L.C.) and Division of Pharmacotherapy and Experimental Therapeutics (H.C., R.S.E., D.R.T.), UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Hao Cai
- Division of Molecular Pharmaceutics (T.H., W.R.P., C.L.C.) and Division of Pharmacotherapy and Experimental Therapeutics (H.C., R.S.E., D.R.T.), UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Ruth S Everett
- Division of Molecular Pharmaceutics (T.H., W.R.P., C.L.C.) and Division of Pharmacotherapy and Experimental Therapeutics (H.C., R.S.E., D.R.T.), UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | - Dhiren R Thakker
- Division of Molecular Pharmaceutics (T.H., W.R.P., C.L.C.) and Division of Pharmacotherapy and Experimental Therapeutics (H.C., R.S.E., D.R.T.), UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| |
Collapse
|
5
|
Han TK, Everett RS, Proctor WR, Ng CM, Costales CL, Brouwer KLR, Thakker DR. Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. Mol Pharmacol 2013; 84:182-9. [PMID: 23680637 DOI: 10.1124/mol.112.084517] [Citation(s) in RCA: 86] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
Organic cation transporters (OCTs) are members of the solute carrier 22 family of transporter proteins that are involved in absorption, distribution, and excretion of organic cations. OCT3 is localized in the apical (AP) membrane of enterocytes, but the literature is ambiguous about OCT1 (mOct1) localization, with some evidence suggesting a basolateral (BL) localization in human and mouse enterocytes. This is contrary to our preliminary findings showing AP localization of OCT1 in Caco-2 cell monolayers, an established model of human intestinal epithelium. Therefore, this study aims at determining the localization of OCT1 (mOct1) in Caco-2 cells, and human and mouse enterocytes. Functional studies using OCT1-specific substrate pentamidine showed transporter-mediated AP but not BL uptake in Caco-2 cells and human and mouse intestinal tissues. OCT1 inhibition decreased AP uptake of pentamidine by ∼50% in all three systems with no effect on BL uptake. A short hairpin RNA-mediated OCT1 knockdown in Caco-2 cells decreased AP uptake of pentamidine by ∼50% but did not alter BL uptake. Immunostaining and confocal microscopy in all three systems confirmed AP localization of OCT1 (mOct1). Our studies unequivocally show AP membrane localization of OCT1 (mOct1) in Caco-2 cells and human and mouse intestine. These results are highly significant as they will require reinterpretation of previous drug disposition and drug-drug interaction studies where conclusions were drawn assuming BL localization of OCT1 in enterocytes. Most importantly, these results will require revision of the regulatory guidance for industry in the United States and elsewhere because it has stated that OCT1 is basolaterally localized in enterocytes.
Collapse
Affiliation(s)
- Tianxiang Kevin Han
- Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | | | | | | | | | | | | |
Collapse
|
6
|
Han TK, Yoder S, Cao C, Ugen KE, Dao ML. Expression of Streptococcus mutans wall-associated protein A gene in Chinese hamster ovary cells: prospect for a dental caries DNA vaccine. DNA Cell Biol 2001; 20:595-601. [PMID: 11747611 DOI: 10.1089/104454901317095016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The Streptococcus mutans strain GS-5 wall-associated protein A (Wap-A) is a precursor to the extracellular antigen A (AgA), a recognized candidate dental caries vaccine. The full-length wapA gene (wapA-E) and a C-terminal truncated version (wapA-G) encoding the AgA were cloned into the mammalian expression vector pcDNA 3.1/V5/His-TOPO. The resulting constructs were propagated in the Escherichia coli Top10. To investigate the expression of the S. mutans genes in mammalian cells, the above constructs were used to transfect Chinese hamster ovary (CHO) cells in the presence of the cationic lipid pfx-8. Transient expression of the wapA-E and wapA-G genes was observed at 24 h post-transfection, as shown by Western immunoblot analysis using a rabbit antiserum to S. mutans cell wall. Immunochemical staining of the transfected CHO cells showed expression of WapA mainly in the cells and budding vesicles, whereas AgA was found mainly in the transfected cells and extracellular medium. The expression of S. mutans proteins in CHO cells, in either vesicles or soluble form, suggested an antibody response to the above DNA constructs. Work is under way to test the efficacy of these as DNA vaccines against S. mutans.
Collapse
Affiliation(s)
- T K Han
- Department of Biology, College of Arts and Sciences, University of South Florida, Tampa, Florida 33620-5150, USA
| | | | | | | | | |
Collapse
|